The key findings were: Tirzepatide met the primary goal of cardiovascular non-inferiority , confirming it is at least as safe for the heart as dulaglutide It did not quite meet statistical superiority over dulaglutide for MACE, although results trended in favour of tirzepatide Tirzepatide produced significantly greater reductions in HbA1c and body weight than dulaglutide Importantly, because SURPASS-CVOT used an active comparator with established cardiovascular benefit rather than a placebo, demonstrating superiority was inherently more difficult than in earlier placebo-controlled GLP-1 outcome trials
Frequently Asked Questions What is the standard starting dose of tirzepatide for weight loss
Wegovy It is FDA-approved for use in combination with diet and exercise to promote weight loss in obese people
Wegovy es ms eficaz si sigues una dieta equilibrada y saludable, y si realizas ejercicio para quemar caloras y desarrollar msculo
Insight into iron, oxidative stress and ferroptosis: therapy targets for approaching anticancer strategies
Because liposomal glutathione is "pre-protected," you have more flexibility